In August 2025 the NHS began offering a vaccine intended to reduce gonorrhoea infections — the first national programme of its kind anywhere. Sexual health services began offering it to those at highest risk, with availability across English regions rolling out over the following weeks.
It Is Not a Gonorrhoea Vaccine, Exactly
The vaccine used is 4CMenB, developed against meningococcal B disease. It works against gonorrhoea because Neisseria meningitidis and Neisseria gonorrhoeae are closely related bacteria, and immunity to one offers some cross-protection against the other.
That relatedness is also why the protection is partial. Estimates put effectiveness against gonorrhoea at roughly 20 to 40% — far below what people expect from a vaccine.
Why Partial Protection Is Still Worth It
At an individual level, a 20 to 40% reduction in risk is meaningful but plainly not protection you should rely on. At a population level it is a different calculation: UKHSA modelling suggested the programme could avert up to 100,000 cases over a decade and save the NHS millions.
The stronger argument is antibiotic resistance. Gonorrhoea has developed resistance to successive antibiotics, and ceftriaxone-resistant cases are being detected in England. Every infection prevented is an infection that does not need treating, and does not create another opportunity for resistance to develop.
Who Is Eligible
The programme targets those at highest risk — gay and bisexual men with a recent history of multiple partners and a bacterial STI diagnosis in the previous 12 months. Eligibility is assessed at sexual health services, and eligible patients are typically offered mpox, hepatitis A and B and HPV vaccination at the same appointment.
It is free, through sexual health clinics.
What It Does Not Change
This is the part worth being clear about:
- It offers no protection against chlamydia, syphilis, HIV, herpes or anything else
- Even against gonorrhoea, most vaccinated people remain susceptible
- Regular testing remains exactly as important as before
- Condoms remain the more effective single intervention against gonorrhoea transmission
A vaccine that reduces risk by a third is a useful addition to prevention. It is not a substitute for any part of it.
Being Monitored
UKHSA is tracking the impact and effectiveness of the programme, with findings due to be shared with the JCVI. That matters because the effectiveness estimate is drawn from observational data rather than a trial designed for this purpose — real-world results from the English programme will be some of the best evidence available anywhere.
If You Are Not Eligible
The programme is targeted because that is where the modelling shows the greatest benefit, not because gonorrhoea only affects that group. If you are outside the eligible group, the practical protections are unchanged and still work: condoms, regular testing appropriate to your circumstances, and prompt treatment of anything found.
Gonorrhoea is frequently asymptomatic, particularly in throat and rectal infections, which is why testing rather than symptom-watching is what catches it.